These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7383547)

  • 41. Cutaneous reactions to practolol. Clinical and histopathological study.
    Kauppinen K; Niemi KM; Salo OP
    Ann Clin Res; 1976 Aug; 8(4):232-40. PubMed ID: 136919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular reaction to oxprenolol.
    Despopoulos A; Maurice PN
    S Afr Med J; 1976 Aug; 50(35):1352. PubMed ID: 968684
    [No Abstract]   [Full Text] [Related]  

  • 43. Statin-associated ocular disorders: the FDA and ADRAC data.
    Mizranita V; Pratisto EH
    Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tamoxifen and ocular toxicity.
    Ah-Song R; Sasco AJ
    Cancer Detect Prev; 1997; 21(6):522-31. PubMed ID: 9398992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Problems with practolol.
    Wall-Manning HJ
    Drugs; 1975; 10(5-6):336-41. PubMed ID: 1240
    [No Abstract]   [Full Text] [Related]  

  • 46. Reporting adverse drug reactions: characteristics and procedures of three organizations.
    Mindel J
    Surv Ophthalmol; 1994; 38(5):453-5. PubMed ID: 8009428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological changes and practolol.
    Amos HE; Brigden WD
    Lancet; 1976 Dec; 2(7998):1298. PubMed ID: 63765
    [No Abstract]   [Full Text] [Related]  

  • 48. Registry pools reports on ocular side effects.
    Cole H
    JAMA; 1985 Oct; 254(13):1690. PubMed ID: 4032667
    [No Abstract]   [Full Text] [Related]  

  • 49. [From The committee for the Registration of Adverse Effects. Adverse effects following Eraldin therapy].
    Lunde I; Borchgrevink CF
    Tidsskr Nor Laegeforen; 1975 Oct; 95(28):1609. PubMed ID: 1179394
    [No Abstract]   [Full Text] [Related]  

  • 50. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker.
    Shore JH; Fraunfelder FT; Meyer SM
    J Clin Psychopharmacol; 1987 Aug; 7(4):264-7. PubMed ID: 3624510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ocular adverse reactions to drug formulations: core information from the Canadian registry.
    Begg IS
    Can J Ophthalmol; 1984 Aug; 19(5):205-6. PubMed ID: 6478305
    [No Abstract]   [Full Text] [Related]  

  • 52. Ocular side-effects of drugs.
    Willetts GS
    Br J Ophthalmol; 1969 Apr; 53(4):252-62. PubMed ID: 5781034
    [No Abstract]   [Full Text] [Related]  

  • 53. Practolol and ocular toxicity. Antibodies in serum and tears.
    Garner A; Rahi AH
    Br J Ophthalmol; 1976 Oct; 60(10):684-6. PubMed ID: 1087569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Oculocutaneous reactions following treatment with betablockers].
    Erikssen J
    Tidsskr Nor Laegeforen; 1976 Aug; 96(24):1288-9. PubMed ID: 9706
    [No Abstract]   [Full Text] [Related]  

  • 55. Adverse effects experienced by patients taking timolol.
    McMahon CD; Shaffer RN; Hoskins HD; Hetherington J
    Am J Ophthalmol; 1979 Oct; 88(4):736-8. PubMed ID: 507146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Practolol and the safety of other beta blockers.
    Sutherland DC; Wilson JD
    N Z Med J; 1976 Oct; 84(573):282-5. PubMed ID: 12491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Adverse ocular effects to systemic drug therapy].
    Czakó C; Sándor G; Horváth H; Szepessy Z; Nagy ZZ; Kovács I
    Orv Hetil; 2020 Jun; 161(23):951-961. PubMed ID: 32453698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985.
    Nelson WL; Fraunfelder FT; Sills JM; Arrowsmith JB; Kuritsky JN
    Am J Ophthalmol; 1986 Nov; 102(5):606-11. PubMed ID: 3777080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A ranked presentation of the MHRA/CSM (Medicines & Health Care Regulatory Agency/Committee on Safety of Medicines) Drug Analysis Print (DAP) data on practolol.
    Mann RD
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):705-10. PubMed ID: 16088980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.